1509-PUB: Effects of an Early Postpartum Lifestyle Intervention in Women with Gestational Diabetes Mellitus and Newly Diagnosed Diabetes

Abstract

Very few studies have assessed short-term and long-term cardiovascular effects of an early postpartum lifestyle intervention among women with gestational diabetes mellitus and diabetes. The aim of the present study was to examine whether an early postpartum 9-month intensive lifestyle intervention can lead to weight loss and improve cardiovascular risk factors among women with both GDM and newly diagnosed diabetes, and also to investigate these effects in a long term. A total of 83 women who had GDM and were newly diagnosed as type 2 diabetes at 2.6 year after delivery participated in a 9-month intensive lifestyle intervention and a follow-up survey at 6-9 years post-intervention. A total of 68 women finished the 9-month lifestyle intervention and 39 women finished the 6-9 years post-intervention survey. During the first 9-month intervention, women lost their weight at 2.76 kg (-3.81% initial weight) , decreased their waist circumference (-2.88 cm) , body fat (-1.69%) , diastolic blood pressure (-3.49 mm Hg) , fasting glucose (-0.98 mmol/L) and HbA1c (-0.71%) . During the 6-9 years post intervention, women still lost weight (-3.49 kg; -5.14% initial weight) , decreased their waist circumference (-4.03 cm) , and body fat (-1.93%) , but slightly increased their HbA1c (0.26%) , total cholesterol (0.29 mmol/L) and triglycerides (0.17 mmol/L) . The prevalence of using glucose-lowering agents increased from 2.9% at baseline to 35.3% after the 9 month lifestyle intervention, and to 48.7% at 6-9 years post-intervention. An early postpartum 9-month intensive lifestyle intervention could have effects on weight loss, decreased HbA1c and other cardiovascular risk factors among women with GDM and newly diagnosed diabetes. The weight loss effect with a lifestyle intervention can persist for at least 6 years, however, HbA1c levels slightly increased in the long term. Disclosure G.Hu: None. J.Leng: None. H.Liu: None. L.Wang: None. S.Zhang: None. W.Li: None. W.Li: None. X.Yang: None. J.Tuomilehto: Stock/Shareholder; Orion Pharma. Funding This study is supported by the grant from European Foundation for the Study of Diabetes (EFSD) /Chinese Diabetes Society (CDS) /Lilly program for Collaborative Research between China and Europe. Dr. Hu was partly supported by the grant from the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100790) and the National Institute of General Medical Sciences (U54GM104940) of the National Institutes of Health.